文献速递临床试验与 GCP基础与转化研究

自体细胞来源组织工程软骨修复膝关节软骨损伤:随机对照试验研究方案

Autologous-cell-derived, tissue-engineered cartilage for repairing articular cartilage lesions in the knee: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-11-06

这是一项前瞻性随机对照试验,计划纳入100例膝关节全层软骨损伤患者,随机分为两组,分别接受仿生软骨细胞外基质支架联合自体软骨细胞构建的组织工程软骨治疗,或关节镜清理加微骨折手术治疗。主要结局为术后12个月Lysholm评分评估的疗效,次要结局包括IKDC评分、VAS评分、MRI评估的软骨损伤与修复及术后不良事件发生率。该试验旨在验证自体软骨细胞联合同种异体脱细胞软骨基质构建的组织工程软骨修复软骨缺损的效果,为其临床应用提供有利证据。

要点

  • 计划纳入100例膝关节全层软骨损伤患者,随机分为组织工程软骨组与关节镜清理加微骨折手术组。
  • 主要结局为术后12个月Lysholm评分评估的疗效,随访时间点为基线及术后3、6、12、18个月。
  • 次要结局包括IKDC评分、VAS评分、MRI评估的软骨损伤与修复及术后不良事件发生率。

核心结论

  • 该试验旨在验证自体软骨细胞联合同种异体脱细胞软骨基质构建的组织工程软骨用于修复软骨缺损的效果,为其临床应用提供有利证据。

研究设计与样本

  • 这是一项前瞻性随机对照试验,计划纳入100例膝关节全层软骨损伤患者,随机分为两组,分别接受仿生软骨细胞外基质支架联合自体软骨细胞构建的组织工程软骨治疗,或关节镜清理加微骨折手术治疗。
  • 随访时间点为基线及术后3、6、12、18个月共五个时间点。

关键数值与推荐

  • 主要结局为术后12个月Lysholm评分评估的疗效。
  • 次要结局为国际膝关节文献委员会(IKDC)评分、视觉模拟量表(VAS)评分、磁共振成像(MRI)评估的软骨损伤与修复以及术后不良事件发生率。
  • 试验注册于ClinicalTrials.gov,注册号NCT02770209,注册日期2016年5月11日。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spontaneous recovery from articular cartilage injury is difficult, and the ongoing progression of disease can eventually lead to osteoarthritis. Currently, there is no effective non-surgical treatment for articular cartilage injury. Arthroscopic debridement and microfracture surgery are performed for fibrocartilage repair. But fibrocartilage is different from normal articular cartilage, and functional recovery is not satisfactory. Therefore, it is necessary to develop more effective techniques for articular cartilage repair. Progress in material science, cell biology, biomechanics, and bioreactor technology has allowed the development of biomimetic, tissue-engineered osteochondral composites that have shown potential for the repair of damaged cartilage. We prepared biomimetic, tissue-engineered cartilage scaffolds optimized for biochemical composition and structural characteristics. Based on the experience of our pre-clinical studies on animals, a human articular cartilage acellular matrix scaffold was prepared and is in clinical use. The combination of autologous chondrocytes and scaffolds has shown satisfactory results in repairing cartilage defects in preliminary experiments. METHODS: This is a prospective randomized controlled trial. One hundred patients with full-thickness cartilage injury of the knee will be randomly divided into two groups to receive treatment with either tissue-engineered cartilage constructed using biomimetic cartilage extracellular-matrix-oriented scaffolds combined with autologous chondrocytes, or arthroscopic debridement and microfracture surgery. There will be five visiting time points: at baseline, then at 3, 6, 12, and 18 months postoperatively. The primary outcome will be therapeutic efficacy as assessed by the Lysholm score at 12 months postoperatively. The secondary outcomes will be the International Knee Documentation Committee score, Visual Analog Scale score, and cartilage injury and repair as assessed by magnetic resonance imaging as well as the incidence of postoperative adverse events. DISCUSSION: This trial will attempt to verify the use of tissue-engineered cartilage constructed using autologous chondrocytes combined with allogeneic, acellular cartilage matrix for the repair of cartilage defects, thereby providing favorable evidence for its use in clinical practice. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02770209 . Registered on 11 May 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ma N, Wang H, Xu X, et al. Autologous-cell-derived, tissue-engineered cartilage for repairing articular cartilage lesions in the knee: study protocol for a randomized controlled trial. Trials. 2017. PMID: 29110690. doi:10.1186/s13063-017-2251-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。